Next Treatments
Back to Eczema

idrebormilast

TypeTopical StagePhase 2 Latest updateOct 2, 2024Phase 2 results posted

What stands out

  • Blocks PDE4 to lower inflammation in the body
Derived from WHO name stem · MedlinePlus: Difamilast Topical · This is a summary of public records for informational purposes only. It is not medical advice.

Results

Trial: NCT05375955
Clear or almost clear skinAfter 12 weeks
Vehicle Ointment44 people
11 in 100
PF-07038124 0.01% Ointment42 people
24 in 100
PF-07038124 0.03% Ointment42 people
21 in 100
02040
+12
more people in 100 reached it on PF-07038124 0.01% Ointment than on placebo.
The sponsor’s 95% confidence range is 4 fewer to 29 more (out of 100).
+10
more people in 100 reached it on PF-07038124 0.03% Ointment than on placebo.
The sponsor’s 95% confidence range is 6 fewer to 27 more (out of 100).
NCT05375955 · Ages 12+ · Results posted Oct 2024 · This is a summary of trial data for informational purposes only. It is not medical advice.
What is IGA?
  • IGA stands for Investigator's Global Assessment.
  • IGA assessed severity of AD on 5-point scale ranging from 0(clear)to 4(severe)higher scores indicate more severity,reflecting a global consideration of erythema (ery),induration and scaling.As this trial registered it · NCT05375955 (the full definition is there)
Why this trial?

Of idrebormilast’s 2 trials with posted results, NCT05375955 is shown first: of the trials that compared the drug with placebo on a result this page charts, it tested more doses (2). We rank those trials by whether they set out to measure skin clearing, whether they tested the drug on its own, their phase, whether they were randomised, whether they included adults, whether they ran in the US, how many doses they tested, how many US sites they had, their size, and then how recently they finished.

All 2 idrebormilast trials
PostedTrialPhaseAgesPeople
Oct 2024NCT05375955 Shown abovePhase 212+263
Aug 2022EMPORIAPhase 218–70104

History

Earliest recorded event: Dec 21, 2020. This timeline shows events collected by Eczema Radar and may not include the treatment’s full history. Study details reflect the latest registry record available here.

  • Oct 2, 2024Phase 2 results postedA Study to Learn About The Study Medicine (PF-07038124) In Patients With Mild To Moderate Atopic Dermatitis Or Mild To Severe Plaque Psoriasis. ClinicalTrials.gov NCT05375955
  • Jul 31, 2023Phase 2 trial completedA Study to Learn About The Study Medicine (PF-07038124) In Patients With Mild To Moderate Atopic Dermatitis Or Mild To Severe Plaque Psoriasis. ClinicalTrials.gov NCT05375955
  • Sep 26, 2022Phase 2 trial startedA Study to Learn About The Study Medicine (PF-07038124) In Patients With Mild To Moderate Atopic Dermatitis Or Mild To Severe Plaque Psoriasis. ClinicalTrials.gov NCT05375955
  • Aug 26, 2022Phase 2 results postedStudy To Assess Efficacy, Safety, Tolerability And Pharmacokinetics Of PF-07038124 Ointment In Participants With Atopic Dermatitis Or Plaque Psoriasis ClinicalTrials.gov NCT04664153
  • Aug 18, 2021Phase 2 trial completedStudy To Assess Efficacy, Safety, Tolerability And Pharmacokinetics Of PF-07038124 Ointment In Participants With Atopic Dermatitis Or Plaque Psoriasis ClinicalTrials.gov NCT04664153
  • Dec 21, 2020Phase 2 trial startedStudy To Assess Efficacy, Safety, Tolerability And Pharmacokinetics Of PF-07038124 Ointment In Participants With Atopic Dermatitis Or Plaque Psoriasis ClinicalTrials.gov NCT04664153

Sources

Trials